Reig Jofré Poised for New European Acquisitions: How the Catalan Pharma Giant Plans to Expand
Reig Jofré, the family-owned Catalan pharmaceutical company, is preparing to make new acquisitions in Europe, leveraging its proven strategy of strategic international expansion. With the backing of its shareholder board—led by the third generation of the founding family—and fresh financial instruments, the company is eyeing markets like Italy, Germany, and deeper integration in France, Poland, and the UK.
For a company that has grown from a local player to a fifth-largest Spanish pharmaceutical firm, Reig Jofré’s next chapter hinges on its ability to replicate the success of past acquisitions like Bioglan in 2009 and Natraceutical in 2015. Now, CEO Ignasi Biosca and his team are positioning the company to make bold moves in a competitive European market.
Proven Playbook: Bioglan and Natraceutical as Blueprints
Reig Jofré’s track record of strategic acquisitions speaks volumes. In 2009, the company acquired Bioglan AB, a Swedish dermatological pharmaceutical manufacturer, marking its first international production facility in Malmö. This move not only expanded its product portfolio but also established a direct presence in the Nordic market. The acquisition cost was €7 million, a significant investment that paid off by diversifying Reig Jofré’s revenue streams and enhancing its global footprint.
Six years later, in 2015, Reig Jofré merged with Natraceutical, a European leader in nutritional supplements sold through pharmacies under the Forté Pharma brand. This merger catapulted Reig Jofré to become the fifth-largest pharmaceutical company listed on the Spanish stock market, solidifying its position as a major player in the industry.
“The Bioglan and Natraceutical acquisitions were pivotal. They allowed us to leverage our core competencies while entering new markets and complementing our existing portfolio.”
Fresh Capital, New Opportunities
The company’s shareholder board, with the founding family retaining 63% of the capital, recently approved the issuance of new ordinary shares and, for the first time, non-voting Series B shares, as well as debt instruments such as convertible bonds and warrants. These new financial tools are designed to fund future acquisitions that align with the company’s strategic vision.
Ignasi Biosca emphasized that the focus remains on “strategic fit,” ensuring that any new acquisition complements Reig Jofré’s existing operations and expands its market reach. The company is particularly interested in markets where it currently has a limited presence, such as Italy and Germany, as well as deepening its footprint in France, Poland, and the UK.
Key Financial and Strategic Moves
- New Shares: Ordinary and non-voting Series B shares approved for issuance.
- Debt Instruments: Convertible bonds and warrants to be used for acquisitions.
- Target Markets: Italy, Germany, France, Poland, and the UK.
- Revenue Growth: 17% increase in sales in 2023, reaching €316 million.
- Operational Growth: 15% rise in EBITDA, reaching €35 million.
Expanding Eastward: The Chequia and Beyond Strategy
In a move that underscores its ambition, Reig Jofré opened a new subsidiary in the Czech Republic in 2024, marking its ninth direct market presence. The company is also exploring further expansion into Slovakia and Hungary, following its successful entry into Poland. This push into Eastern Europe is part of a broader strategy to capitalize on growth opportunities in regions where it has not yet established a direct presence.
Ignasi Biosca highlighted that the company’s goal for 2024 is to grow faster than the broader market, leveraging its strong financial performance and strategic acquisitions to drive profitability and market share.
“Our strategy is clear: grow where we have a competitive edge and fill gaps in our portfolio. The Eastern European market is a prime example of where we can make a significant impact.”
What’s Next for Reig Jofré?
As Reig Jofré prepares to make its next move, the company’s focus remains on acquisitions that offer both strategic and financial benefits. The recent approval of new financial instruments signals confidence in its ability to execute these plans, while its history of successful mergers and acquisitions provides a strong foundation for future growth.
The next confirmed checkpoint for Reig Jofré is the rollout of its new subsidiary in the Czech Republic, with plans to further solidify its presence in Eastern Europe and explore opportunities in Italy and Germany. The company’s ability to replicate the success of Bioglan and Natraceutical will be key to its continued expansion and dominance in the European pharmaceutical market.
What do you think about Reig Jofré’s expansion plans? Will these acquisitions help solidify its position as a European pharma leader? Share your thoughts in the comments below.
